person · Reporting owner
ALTSTIEL LARRY DOUGLAS
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Chief Medical Officer | September 22, 2025 | September 24, 2025 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Chief Medical Officer | March 10, 2017 | March 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date September 22, 2025 · Filed September 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2035-09-22 | Direct | 165,000 |
Reported balance
After 2025-09-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-22 · Grant · Acquired 165,000 · Balance 165,000 F1: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months
vTv Therapeutics Inc.
Report date March 10, 2017 · Filed March 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81 · Expires 2027-03-10 | Direct | 268,085 |
Reported balance
After 2017-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-10 · Grant · Acquired 128,085 · Balance 268,085 F1: The option vests in three equal annual installments beginning March 10, 2018 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments beginning March 10, 2018
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2025 Filed Sep 24, 2025 12:45 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001619444-25-000002 · primary_doc.xml · derivative · entry 1 ALTSTIEL LARRY DOUGLAS · CIK 0001619444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Shares · 165,000 shares Expires 2035-09-22 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months Read SEC document |
| November 18, 2024 Filed Nov 21, 2024 00:01 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-24-121132 · tm2429073-1_4seq1.xml · derivative · entry 1 ALTSTIEL LARRY DOUGLAS · CIK 0001619444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Shares · 175,000 shares Expires 2034-11-18 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 23:46 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000950170-23-056500 · ownership.xml · derivative · entry 1 ALTSTIEL LARRY DOUGLAS · CIK 0001619444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-10-26 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on October 26, 2024, and the balance shall vest ratably over 36 months. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 16:04 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 128,085 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001562180-17-001253 · primarydocument.xml · derivative · entry 1 ALTSTIEL LARRY DOUGLAS · CIK 0001619444 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,085 Underlying: Class A Common Stock · 128,085 shares Expires 2027-03-10 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning March 10, 2018 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.